1
Participants
Start Date
July 31, 2012
Primary Completion Date
August 31, 2013
Study Completion Date
August 31, 2013
Fluticasone propionate (with and without concurrent salmeterol)
"Fluticasone propionate is an inhaled corticosteroid used for the treatment of asthma, often in combination with the long-acting β-agonist salmeterol. For the primary endpoint, exposure status will be determined based on the individual receiving a prescription for the drug of interest (fluticasone propionate or another inhaled corticosteroid) in the 2 weeks immediately before the LMP date or during the first trimester of pregnancy.~Sensitivity analysis will be carried out categorising exposure based on mapping the duration of prescriptions based on the number of inhalers, number of puffs within an inhaler and the prescribed daily dose."
Lead Sponsor
GlaxoSmithKline
INDUSTRY